JPH11513572A5 - - Google Patents

Info

Publication number
JPH11513572A5
JPH11513572A5 JP1997516288A JP51628897A JPH11513572A5 JP H11513572 A5 JPH11513572 A5 JP H11513572A5 JP 1997516288 A JP1997516288 A JP 1997516288A JP 51628897 A JP51628897 A JP 51628897A JP H11513572 A5 JPH11513572 A5 JP H11513572A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997516288A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11513572A (ja
JP3966903B2 (ja
Filing date
Publication date
Priority claimed from DE19539493A external-priority patent/DE19539493A1/de
Application filed filed Critical
Publication of JPH11513572A publication Critical patent/JPH11513572A/ja
Publication of JPH11513572A5 publication Critical patent/JPH11513572A5/ja
Application granted granted Critical
Publication of JP3966903B2 publication Critical patent/JP3966903B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP51628897A 1995-10-24 1996-10-24 ハムスターの強力な同種プロモーター Expired - Lifetime JP3966903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19539493A DE19539493A1 (de) 1995-10-24 1995-10-24 Starker homologer Promotor aus Hamster
DE19539493.3 1995-10-24
PCT/EP1996/004631 WO1997015664A1 (de) 1995-10-24 1996-10-24 Starker homologer promotor aus hamster

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006187719A Division JP2006320330A (ja) 1995-10-24 2006-07-07 ハムスターのユビキチン遺伝子

Publications (3)

Publication Number Publication Date
JPH11513572A JPH11513572A (ja) 1999-11-24
JPH11513572A5 true JPH11513572A5 (2) 2004-08-12
JP3966903B2 JP3966903B2 (ja) 2007-08-29

Family

ID=7775593

Family Applications (2)

Application Number Title Priority Date Filing Date
JP51628897A Expired - Lifetime JP3966903B2 (ja) 1995-10-24 1996-10-24 ハムスターの強力な同種プロモーター
JP2006187719A Pending JP2006320330A (ja) 1995-10-24 2006-07-07 ハムスターのユビキチン遺伝子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006187719A Pending JP2006320330A (ja) 1995-10-24 2006-07-07 ハムスターのユビキチン遺伝子

Country Status (11)

Country Link
US (1) US6063598A (2)
EP (2) EP1803815A3 (2)
JP (2) JP3966903B2 (2)
AT (1) ATE355370T1 (2)
CA (1) CA2234071C (2)
DE (2) DE19539493A1 (2)
DK (1) DK0857211T3 (2)
ES (1) ES2281905T3 (2)
MX (1) MX9802764A (2)
PT (1) PT857211E (2)
WO (1) WO1997015664A1 (2)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0961830A1 (en) * 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
EP1624067A3 (en) * 2000-09-18 2006-03-15 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
AU2001290984A1 (en) * 2000-09-18 2002-04-02 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
ATE466941T1 (de) * 2001-07-04 2010-05-15 Chromagenics Bv Dns-sequenzen mit anti-repressor-aktivität
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
US7344886B2 (en) 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10256083A1 (de) 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
US20050101017A1 (en) * 2003-11-10 2005-05-12 Wojtek Auerbach Method of improving gene targeting using a ubiquitin promoter
GB0509965D0 (en) * 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
US9163257B2 (en) * 2005-06-20 2015-10-20 Cadila Healthcare Limited Expression vector and methods of producing high levels of proteins
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2938726B1 (en) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologous intron within a signal peptide
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US9989540B2 (en) 2013-05-10 2018-06-05 The Regents Of The University Of California Diagnostic and monitoring system for Huntington's disease
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
EP3089760B1 (en) 2013-12-31 2020-01-15 ProteoNic Biotechnology IP B.V. Construct and sequence for enhanced gene expression
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
HRP20230405T8 (hr) 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2016186879A1 (en) 2015-05-18 2016-11-24 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
EP3323166B1 (en) 2015-07-15 2024-03-13 ZYMtronix, Inc. Automated bionanocatalyst production
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
CA3031802A1 (en) 2016-08-13 2018-02-22 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals
CN110177869A (zh) 2017-01-13 2019-08-27 加利福尼亚大学董事会 免疫改造的多能细胞
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
CU20200042A7 (es) 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
US20210263001A1 (en) 2018-09-05 2021-08-26 Zymtronix Catalytic Systems, Inc. Immobilized enzymes and microsomes on magnetic scaffolds
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN119684457A (zh) 2018-11-26 2025-03-25 四十七有限责任公司 针对c-kit的人源化抗体
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
WO2020231882A2 (en) 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
US12391923B2 (en) 2019-06-26 2025-08-19 The Regents Of The University Of California SIRPα-silenced natural killer (NK) cells
JP2022543112A (ja) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド Ｄｕｘ４発現細胞およびそれらの使用
AU2020336302A1 (en) 2019-08-23 2022-03-03 Sana Biotechnology, Inc. CD24 expressing cells and uses thereof
AU2021207810A1 (en) 2020-01-13 2022-08-04 Sana Biotechnology, Inc. Modification of blood type antigens
EP4585223A3 (en) 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
CA3165076A1 (en) 2020-01-17 2021-07-22 Ryan Clarke Safety switches for regulation of gene expression
MX2022011831A (es) 2020-03-25 2023-01-04 Sana Biotechnology Inc Células neurales hipoinmunogénicas para el tratamiento de trastornos y afecciones neurológicas.
CA3183994A1 (en) 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
IL300516A (en) 2020-08-13 2023-04-01 Sana Biotechnology Inc Methods for treating susceptible patients with hypoimmunogenic cells, and related methods and compounds
CA3200509A1 (en) 2020-12-31 2022-07-07 Sonja SCHREPFER Methods and compositions for modulating car-t activity
BR112023024231A2 (pt) 2021-05-19 2024-01-30 Sana Biotechnology Inc Células t primárias rhd negativas hipoimunogênicas
AU2022283291A1 (en) 2021-05-27 2023-11-02 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
WO2023019226A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
KR20240073006A (ko) 2021-08-11 2024-05-24 사나 바이오테크놀로지, 인크. 동종이계 세포 요법을 위한 유전자 변형된 1차 세포
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
US20250101382A1 (en) 2022-03-11 2025-03-27 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
CN121604968A (zh) 2023-05-22 2026-03-03 萨那生物科技公司 递送胰岛细胞的方法及相关方法
AU2024328949A1 (en) 2023-08-23 2026-03-12 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
AU2024342922A1 (en) 2023-09-15 2026-04-23 Othair Prothena Limited Cell penetrating agents and uses thereof
TW202525338A (zh) 2023-09-15 2025-07-01 愛爾蘭商普羅希那生物科學有限公司 細胞穿透劑及其用途
AR133828A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
AU2024342899A1 (en) 2023-09-15 2026-04-23 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
WO2025166633A2 (en) 2024-02-07 2025-08-14 Westlake Genetech. Ltd. Split gene editing systems and uses thereof

Similar Documents

Publication Publication Date Title
JP2000500445A5 (2)
JP2000500228A5 (2)
JP2000500033A5 (2)
JP2000500440A5 (2)
JP2000500327A5 (2)
JPH11513572A5 (2)
JP2000500406A5 (2)
JP2000500361A5 (2)
JPH11505082A5 (2)
JP2000500322A5 (2)
JP2000502117A5 (2)
JP2000500258A5 (2)
JPH11512593A5 (2)
JP2000500342A5 (2)
JP2000500112A5 (2)
JPH11507753A5 (2)
JP2000500226A5 (2)
JP2000500051A5 (2)
JP2000500397A5 (2)
JP2000500407A5 (2)
JP2000500019A5 (2)
JP2002515968A5 (2)
JPH11510569A5 (2)
JP2000500346A5 (2)
JP2000500044A5 (2)